Primer Hiperkolesterolemili Yakalarda Kısa Süreli Pravastatmm Etkinliği

SuleymanDemirel Universitesi TIP FAKULTESI DERGISI: 1998 Aralik; 5(4) Primer Hiperkolesterolemili Yakalarda Kisa Sureli Pravastatmm Etkinligi Abdullah Dogan, Ahmet Altinbas, Fehmi Ozguner OZET Anjiyografik calismalarda, serum kolesterol duzeylerinin azaltilmasiyla, koroner atherosklerozun geriledigi gos¬terilmistir. Calismamizda, primer hiperkolesterolemui hastalarda, pravastatinin kisa sureli etkinligini ve yan etki pro¬fili incelendi. Diyete ragmen, hiperkolesterolemisi devam eden 26'si erkek, 19'u kadin 45 hasta calismaya alindi. Yas ortala¬masi 5520±11.62 yildi. Aktif karaciger hastaligi olanlar, uc ay icinde miyokard infarktusu gecirenler ve kolesterol duzeyini etkileyebilecek ilac kullananlar calisma disi birakildi. Vakalarin %54 'unde kesin koroner arter hastaligi var¬di. Hastalara uc ay boyunca 10 mg/gun pravastatin verildi. Total kolesterolde %19 (294.40*37.04-239.75±32.76 mg/dL), LDL kolesterolde %27 (213.90+36,30-156.31'±34.01 mg/dL) ve trigliseritte %30 (169.33±15.45-118.34+38.27 mg/dL) azalma gozlendi. HDL kolesterolde ise %17 (47.29±963-553±8.54 mg/dL) artis bulundu. Tum sonuclar anlamliydi (p<0.0001). Hicbir hastada yan etki nedeniyle ilac kesilmedi. Sonuc olarak, primer hiperkolesterolemui vakalarda pravastatin kisa sureli etkin ve guvenilirdir. Ancak hedefle¬nen kolesterol seviyelerine ulasmada 10 mg/gun dozu yeterli degildir. Anahtar Kelimeler: Pravastatin, hiperkolesterolemi, tedavi ABSTRACT EFFECTIVENESS OF SHORT-TERM PRAVASTATIN IN PATTENTS WITH PRIMER HYPERCHO-LESTEROLEMIA in angiographic studies, the regression in coronary atherosclerosis has been showed by lowering serum choles-terol levels. We examined the effectiveness and tolerability of pravastatin in patients with primer hypercholesterole-mia. Inspite ofdiet, 45 patients (26 male, 19female) with primer hypercholesterolemia were admitted to this study. Me an age ofthem was 55.20±11.62 years. Patients with active hepatic disease, using drugs to affect the cholesterol le¬vels, and having myocardial infarction in last three months were excluded. Pravastatin 10 mg/day was administered to the patients during three months. Total cholesterol dropped by %19 (239.75±32.76 from 294.40±37.04 mg/dL), LDL cholesterol dropped by %27 (15637±34.01 from 213.90±36.30 mg/dL), triglyseride levels dropped by %30 (11834±3820from 169.33±15.45 mg/dL) whue HDL cholesterol increased by %17 (from 47.29±9.63-55.53±854 mg/dL). The results were significant (p<0.0001). There were no patients stopping the drug owing to side-effects. in conclusion, pravastatin can be used effective and safety in patients with hypercholesterolemia. However, 10 mg/day dose is not enough to achieve the goals. Key Words: Pravastatin, hypercholesterolemia, treatment